Clinical Trial Update: Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating genetically modified KIND T cells for HLA-A*0201-positive patients with diffuse midline glioma harboring H3 K27 mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Midline Glioma H3 K27-altered

Drugs mentioned

• KIND T Cells

Snippet

Sponsor: University of California, San Francisco | Conditions: Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Status: ACTIVE_NOT_RECRUITING